Stem Cell Transplantation

A novel regimen significantly reduced risk for moderate to severe chronic graft-versus-host disease for certain patients who underwent allogeneic hematopoietic stem cell transplantation, according to randomized phase 2 study results.

Taking prescribed beta blockers during hematopoietic stem cell transplantation may increase mortality risk due to suppression of signals from nerves that promote bone marrow regeneration, according to study results.

Patients with myelofibrosis who cleared driver mutations within 30 days after hematopoietic stem cell transplantation survived longer and exhibited reduce risk for relapse, according to study results.

Clonal hematopoiesis did not occur significantly more often among patients who received hematopoietic stem cell transplantation than their donors, according to findings of a correlative laboratory study.

A seventh person has potentially been cured of HIV after receiving a stem cell transplant to treat blood cancer, researchers announced on the eve of the 25th International AIDS Conference.

In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, discusses what she would like to see in the future of myleoproliferate neoplasms care and management.

Editor’s note: This is the first in a series of five stories from ASCO Voices, a session during the 2024 ASCO Annual Meeting focused on the human side of oncology.

CHICAGO — Interim results from a phase 2 study showed positive survival outcomes for individuals who underwent peripheral blood stem cell transplantation for hematologic malignancies.

DESTIN, Fla. — Stem cell transplantation, accompanied by total body radiation, is the only “cure” for progressive systemic sclerosis currently available, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

Nearly one-half of adults with relapsed or refractory CD19-positive B-cell malignancies responded to treatment with a novel cord blood-derived natural killer cell therapy expressing a chimeric antigen receptor, study results showed.